Earning Analysis
Welcome to our in-depth analysis of Boston Scientific Corp(BSX) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Boston Scientific Corp earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-10-22 | Pre-Market | 0.71 | 0.75 | +5.63 | 4.97B | 5.07B | +1.83 | +3.95 | +2.53 |
| FY2025Q2 | 2025-07-23 | Pre-Market | 0.72 | 0.75 | +4.17 | 4.89B | 5.06B | +3.39 | +4.46 | +2.60 |
| FY2025Q1 | 2025-04-23 | Pre-Market | 0.67 | 0.75 | +11.94 | 4.57B | 4.66B | +1.98 | +4.07 | +7.50 |
| FY2024Q4 | 2025-02-05 | Pre-Market | 0.65 | 0.70 | +7.69 | 4.42B | 4.56B | +3.16 | +1.38 | +2.36 |
| FY2024Q3 | 2024-10-23 | Pre-Market | 0.58 | 0.63 | +8.62 | 4.04B | 4.21B | +4.15 | -0.64 | -3.92 |
| FY2024Q2 | 2024-07-24 | - | 0.58 | 0.62 | +6.90 | 4.02B | 4.12B | +2.46 | -1.06 | -5.80 |
| FY2024Q1 | 2024-04-24 | - | 0.51 | 0.56 | +9.80 | 3.68B | 3.86B | +4.65 | +5.68 | +4.17 |
| FY2023Q4 | 2024-01-31 | - | 0.51 | 0.55 | +7.84 | 3.60B | 3.73B | +3.57 | +3.00 | +5.49 |
| FY2023Q3 | 2023-10-26 | - | 0.48 | 0.50 | +4.17 | 3.48B | 3.53B | +1.44 | -0.42 | +3.34 |
| FY2023Q2 | 2023-07-27 | - | 0.49 | 0.53 | +8.16 | 3.50B | 3.60B | +2.73 | +0.46 | -3.40 |
BSX Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Boston Scientific Corp reported performance for FY2025Q3, announced on 2025-10-22. The company achieved an EPS of 0.75, compared to analyst estimates of 0.71 by 5.63% . Revenue for the quarter reached 5.07B compared to expectations of 4.97B by 1.83% .
The stock price reacted with a 3.95% one-day change and a 2.53% five-day change following the earnings release. These movements reflect market reaction in Boston Scientific Corp growth trajectory and strategic initiatives.
BSX Earnings Forecast
Looking ahead, Boston Scientific Corp(BSX) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 5.28B and an EPS of 0.78.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 1.17%, while EPS estimates have been Revise Upward by 1.74%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 2.08% . These revisions correlate with a -8.86% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Boston Scientific Corp long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between BSX's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+1.17%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+1.74%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
+2.08%
In Past 3 Month
Stock Price
Go Down
-8.86%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:20.08B
--
EPS Estimate-Annual FY 2025:3.03
—
Stock Price97.72
BSX Revenue and EPS Performance: A Historical Perspective
Boston Scientific Corp revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-10-22,Pre-Market):
EPS: 0.75 (Actual) vs.0.71 (Estimate) (5.63%)
Revenue: 5.07B (Actual) vs. 4.97B (Estimate) (1.83%)
Price Reaction: 3.95%(1-Day), 2.53%(5-Day)
FY2025Q2 (2025-07-23,Pre-Market):
EPS: 0.75 (Actual) vs.0.72 (Estimate) (4.17%)
Revenue: 5.06B (Actual) vs. 4.89B (Estimate) (3.39%)
Price Reaction: 4.46%(1-Day), 2.60%(5-Day)
FY2025Q1 (2025-04-23,Pre-Market):
EPS: 0.75 (Actual) vs.0.67 (Estimate) (11.94%)
Revenue: 4.66B (Actual) vs. 4.57B (Estimate) (1.98%)
Price Reaction: 4.07%(1-Day), 7.50%(5-Day)
Earnings Reaction
The chart below shows how BSX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BSX sees a -3.73% change in stock price 10 days leading up to the earnings, and a -0.53% change 10 days following the report. On the earnings day itself, the stock moves by +2.09%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -1.41% on the day following the earnings release and then changed by -4.77% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Boston Scientific Corp (BSX) Q3 2025 Earnings Call Summary
Positive
2025-10-22
The earnings call reflects strong financial performance and optimistic guidance, with raised full-year guidance for organic growth and EPS. The Q&A section highlights promising growth drivers, including new product launches and strategic acquisitions. Despite some concerns about backorders and management's vague responses, the overall sentiment is positive, driven by robust revenue and margin growth, as well as strategic market positioning.
Boston Scientific Corp (BSX) Q2 2025 Earnings Call Summary
Positive
2025-07-23
The earnings call presents strong financial performance with 22.8% revenue growth and optimistic guidance for organic growth and EPS. Despite a gross margin decline due to inventory charges, the company's strategic investments in product development and market expansion suggest future growth. The Q&A highlights potential risks like physician fee reductions but overall maintains a positive outlook, supported by strong sales and strategic initiatives. The lack of market cap data prevents assessing small-cap volatility, but the overall sentiment leans positive due to strong earnings and guidance.
Boston Scientific Corp (BSX) Q1 2025 Earnings Call Summary
Positive
2025-04-24
The earnings call highlights strong financial performance, with impressive revenue and EPS growth, and positive guidance for 2025. Despite tariff challenges, the company plans to offset these with increased sales and spending cuts. Product development is strong, with new launches and acquisitions. Share repurchase plans add to positive sentiment. However, risks like competitive pressures and regulatory challenges exist. The Q&A section shows confidence in managing these risks, supporting a positive outlook.
Earnings call transcript: Boston Scientific Q3 2024 shows strong growth
Positive
2025-01-22
The earnings call indicates strong financial performance, with revenue and EPS growth exceeding expectations. The company has raised guidance, indicating optimism. Despite some regulatory and competitive risks, the management's confidence in product performance and upcoming launches is reassuring. The shareholder return plan includes share repurchases, which are positive. While there are concerns about supply chain and competitive pressures, the overall sentiment is positive, supported by strong operational sales and EPS growth.
Boston Scientific Corporation (BSX) Business Update Earnings Call Summary
Positive
2024-11-02
The earnings call highlights strong financial performance, including revenue growth exceeding guidance and a raised full-year outlook. New product developments and strategic acquisitions are expected to support future growth. The Q&A session addressed concerns effectively, maintaining confidence in the company's strategy and regulatory progress. Despite some uncertainties with FDA discussions, the positive sentiment from analysts and management's optimistic outlook suggest a positive stock price movement. The lack of market cap data prevents a precise prediction, but the overall sentiment leans towards a positive impact in the short term.
Boston Scientific Corporation (BSX) Q3 2024 Earnings Call Summary
Positive
2024-10-23
The company has demonstrated strong financial performance with a 19% sales growth and 27% EPS increase. Positive guidance for both organic growth and EPS, along with a robust cash flow, indicates strong future prospects. Despite some regulatory and competitive risks, new product launches and strategic acquisitions bolster confidence. Management's cautious optimism in the Q&A reflects a positive sentiment. The overall sentiment leans positive, with an expectation of a stock price increase of 2% to 8% over the next two weeks.
Boston Scientific Corporation (BSX) Q2 2024 Earnings Call Summary
Positive
2024-07-24
The earnings call highlights strong financial performance, with organic sales growth exceeding guidance and positive EPS results. The guidance for both Q2 and full-year 2024 has been raised, indicating confidence in future performance. Despite some risks like foreign exchange impact and regulatory approvals, the company's strategic acquisitions and product launches show promise. The Q&A section reflects optimism about growth drivers and market position. Although there are risks, the strong financial metrics and optimistic guidance suggest a positive stock price movement in the short term.
People Also Watch
FAQ
What were the key highlights of BSX’s latest earnings report for FY2025Q3?
How did BSX’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for BSX for 2025/Q4?
How does BSX’s stock price correlate with earnings forecast revisions?
What should investors expect from BSX’s next earnings report?